Type 1 Diabetes Market Report 2026

The type 1 diabetes market size has grown rapidly in recent years. It will grow from $13.5 billion in 2025 to $15.27 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to improved availability of insulin analogs, rising diagnosis rates in pediatric populations, expansion of diabetes specialty care centers, increased awareness of autoimmune diabetes, advancements in glucose monitoring technologies.

The type 1 diabetes market size is expected to see rapid growth in the next few years. It will grow to $25.73 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to growing adoption of closed-loop insulin delivery systems, rising investments in immunotherapy research, increasing focus on disease-modifying treatments, expansion of digital diabetes management platforms, growing demand for patient-centric care models. Major trends in the forecast period include increasing adoption of continuous glucose monitoring systems, rising use of insulin pump technologies, growing focus on personalized insulin therapy, expansion of combination therapy approaches, enhanced emphasis on early diagnosis and disease management.

The rising prevalence of obesity and heart disease is expected to drive the growth of the type 1 diabetes market going forward. Obesity and heart disease are known to increase insulin resistance and metabolic stress, which can exacerbate the onset and progression of type 1 diabetes. The type 1 diabetes market supports patients by offering therapies such as rapid-acting insulin analogs, long-acting insulin analogs, premix insulin formulations, and continuous glucose monitoring systems that help manage blood glucose levels and reduce the risk of complications. For example, in 2023, according to the Centers for Disease Control and Prevention (CDC), approximately 1.6 million Americans were living with type 1 diabetes. Additionally, in 2022, Diabetes Canada reported that the number of Canadians diagnosed with type 1 diabetes reached around 0.0037 million. Therefore, the increasing burden of obesity and heart disease is fueling demand in the type 1 diabetes market.

Leading companies in the type 1 diabetes market are investing in innovative treatments, such as allogeneic islet cell transplantation, aimed at restoring functional beta cells and reducing patients’ reliance on insulin. Allogeneic islet cell transplantation involves the infusion of donor pancreatic islet cells into the patient’s hepatic portal vein to re-establish endogenous insulin production and decrease hypoglycemic episodes and the need for insulin injections. For instance, in June 2023, CellTrans Inc., a US-based biotechnology firm, received FDA approval for Lantidra (donislecel), the first cellular therapy for type 1 diabetes. This approval represents a significant advance in regenerative medicine, offering a potential long-term solution for patients struggling with insulin dependence. Lantidra functions by replacing the insulin-producing cells destroyed by the immune system, aiming to restore natural glucose regulation in the body.

In March 2023, Sanofi, a France-based pharmaceutical and healthcare company, acquired Provention Bio Inc. for $2.9 billion. Through this acquisition, Sanofi intends to strengthen its portfolio in immune-mediated diseases and disease-modifying therapies in areas with high unmet need, leveraging its diabetes expertise to enhance the potential of transformative treatments. Provention Bio, Inc., a US-based biopharmaceutical company, specializes in the development and manufacturing of products for type 1 diabetes.

Major companies operating in the type 1 diabetes market are Johnson and Johnson Limited, Merck and Co. Inc., Sanofi-Aventis LLC, Abbott Laboratories, Medtronic Plc, Eli Lilly and Co Ltd, Novo Nordisk A/S, Dexcom Inc, Insulet Corporation, Tandem Diabetes Care Inc, Adaptive Biotechnologies Corporation, Xeris Pharmaceuticals Inc, MannKind Corporation, Biocon Ltd, Virta Health Corp, Bigfoot Biomedical Inc, ViaCyte Inc, Beta Bionics Inc, Adocia SA, Senseonics Holdings Inc, Zealand Pharmaceuticals A/S, Provention Bio Inc.

North America was the largest region in the type 1 diabetes market in 2025. The regions covered in the type 1 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the type 1 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the type 1 diabetes market by increasing costs of imported insulin analogs, glucose sensors, infusion sets, electronic monitoring devices, and pharmaceutical manufacturing inputs. North America and Europe are particularly affected due to dependence on cross-border pharmaceutical supply chains, while Asia-Pacific faces cost pressure on device components and consumables. These tariffs are raising treatment costs and affecting affordability for patients and healthcare providers. However, they are also encouraging localized drug manufacturing, regional device assembly, and increased investment in domestic biopharmaceutical production capabilities.

The type 1 diabetes market research report is one of a series of new reports that provides type 1 diabetes market statistics, including type 1 diabetes industry global market size, regional shares, competitors with a type 1 diabetes market share, detailed type 1 diabetes market segments, market trends and opportunities, and any further data you may need to thrive in the type 1 diabetes industry. This type 1 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Type 1 diabetes, also called juvenile diabetes or insulin-dependent diabetes, is a long-term condition that impacts the body's ability to manage blood sugar levels. It occurs when the immune system mistakenly destroys the beta cells in the pancreas responsible for producing insulin.

The primary categories of type 1 diabetes treatments include rapid-acting insulin analogs, long-acting insulin analogs, premix insulin analogs, and others. Rapid-acting insulin analogs are synthetic forms of insulin modified from natural insulin to act faster, reach peak effect sooner, and have a shorter duration of action. The treatment devices include insulin pumps, insulin pens, and blood glucose meters, which are used in various settings, including by children and adults, as well as by different end-users such as hospitals, research institutions, and home care.

The type 1 diabetes market consists of sales of drugs used to treat type 1 diabetes such as autoimmune type 1 diabetes and idiopathic type 1 diabetes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.